Ye Sel Kim, Moo-Seok Park, Jun-Hwa Lee, Jong-Won Chung, Mi Ji Lee, Chi Kyung Kim, Jin-Man Jung, Kyungmi Oh, Oh Young Bang, Geong-Moon Kim, Ji-Mi Choi, Juneyoung Lee, Chin Sang Chung, Kwang Ho Lee, Woo-Keun Seo
Abstract
The objective of this study was to investigate the potential benefits of statin therapy initiation in acute stroke in patients with active cancer. This study was conducted in two parts. First, data from patients who are presented with stroke and active cancer were obtained from prospectively collected multicenter hospital-based stroke registries. Patients were classified into statin user and non-user groups; the statin group was further divided into low-potency and high-potency statin subgroups. The primary outcome was time to mortality. Second, we obtained data from the Korean National Health Information Service-National Sample Cohort (NHIS-NSC) database for external validation and analyzed the effect of statins on mortality, taking compliance into consideration. For the stroke registry cohort, statin use was independently associated with reduced mortality in a multivariable model [hazard ratio (HR) = 0.675, 95% confidence interval (CI) = 0.457-0.996]. There was no interaction between statin use and cancer characteristics, vascular risk factors, or laboratory findings. A dose-dependent relationship between statin use and survival was also demonstrated. Analysis of the NHIS-NSC database found a similar association between statin therapy and reduced mortality (adjusted HR = 0.64, 95% CI = 0.45-0.90) and this effect persisted even after controlling for the adherence of statin use (HR = 0.60, 95% CI = 0.41-0.89). Statin therapy could be associated with reduced mortality in patients with acute stroke and active cancer.
Pharmacology, Toxicology and Pharmaceutical Science
4
27%
Biochemistry, Genetics and Molecular Biology
1
7%
Nursing and Health Professions
1
7%
Psychology
1
7%
Medicine and Dentistry
1
7%
Other
1
7%
Unknown
6
40%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 May 2018.
All research outputs
#14,981,465
of 23,045,021 outputs
Outputs from Frontiers in Neurology
#6,178
of 11,948 outputs
Outputs of similar age
#197,119
of 326,487 outputs
Outputs of similar age from Frontiers in Neurology
#150
of 292 outputs
Altmetric has tracked 23,045,021 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 11,948 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,487 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 292 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
